Related Experiment Video
Updated: May 10, 2026
Activation and Measurement of NLRP3 Inflammasome Activity Using IL-1β in Human Monocyte-derived Dendritic Cells
Published on: May 22, 2014
Non-coding RNAs affecting NLRP3 inflammasome pathway in diabetic cardiomyopathy: a comprehensive review of potential
Elahe Radmehr1,2, Niloufar Yazdanpanah3,2,4, Nima Rezaei5,6,7
1Colorectal Research Center, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
Insights
Diabetic cardiomyopathy (DCM) is rising globally, driven by diabetes mellitus. Non-coding RNAs targeting the NLRP3 inflammasome offer promising therapeutic avenues for treating this heart condition.
Area of Science:
- Cardiology
- Molecular Biology
- Genetics
Background:
- Cardiomyopathies are a diverse group of heart muscle disorders leading to heart failure and sudden death.
- The global prevalence of cardiomyopathies, particularly diabetic cardiomyopathy (DCM), is increasing due to the rise in diabetes mellitus (DM).
- NLRP3 inflammasome activation is a key factor in the development and progression of DCM.
Purpose of the Study:
- To review non-coding RNAs that target NLRP3 inflammasome signaling.
- To explore the therapeutic potential of these non-coding RNAs in treating DCM.
- To provide an overview for future research in DCM therapeutics.
Main Methods:
- Comprehensive literature review.
- Analysis of studies on non-coding RNAs and NLRP3 inflammasome.
- Focus on therapeutic strategies for DCM.
Main Results:
- Non-coding RNAs show potential in modulating NLRP3 inflammasome pathways.
- Targeting NLRP3 inflammasome signaling presents a novel therapeutic strategy for DCM.
- Identification of specific non-coding RNAs with therapeutic implications.
Conclusions:
- Non-coding RNAs are emerging as significant therapeutic targets for DCM.
- Targeting the NLRP3 inflammasome via non-coding RNAs could offer new treatments for diabetic cardiomyopathy.
- Further research is warranted to develop non-coding RNA-based therapies for DCM.
Abstract:
Cardiomyopathies are a heterogeneous group of disorders that can lead to fulminant heart failure and sudden cardiac death. In recent years, the prevalence of all types of cardiomyopathies has shown an upward trend globally. Up to 40% of patients with cardiomyopathy-related heart failure have diabetes mellitus (DM). With the fast global spread of DM, the prevalence of DCM is increasing accordingly and it remains the leading cause of morbidity and mortality in chronic diabetic patients. NLRP3 inflammasome significantly contributes to the development and pathological progression of DCM. Targeting the inflammasome or any of the mediators along its activation pathway provides new potential therapeutic targets for developing specialized drugs to treat DCM.In this comprehensive review, we sought to introduce and summarize the non-coding RNAs with potential therapeutic effects targeting NLRP3 inflammasome signaling in DCM. We hope this general overview can aid future research in developing new therapies for DCM.
More Related Videos
11:00Assessment of Sarcoplasmic Reticulum Calcium Reserve and Intracellular Diastolic Calcium Removal in Isolated Ventricular Cardiomyocytes
Published on: September 18, 2017
05:58Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
Published on: April 18, 2025
Related Concept Videos
02:26NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
01:25Inflammatory Bowel Disease III: Crohn's Disease